(NASDAQ: FHTX) Foghorn Therapeutics's forecast annual revenue growth rate of 6.25% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 34.35%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 14.04%.
Foghorn Therapeutics's revenue in 2026 is $28,224,000.On average, 12 Wall Street analysts forecast FHTX's revenue for 2026 to be $1,360,519,001, with the lowest FHTX revenue forecast at $188,001,978, and the highest FHTX revenue forecast at $2,052,932,283. On average, 12 Wall Street analysts forecast FHTX's revenue for 2027 to be $2,033,028,263, with the lowest FHTX revenue forecast at $1,150,792,871, and the highest FHTX revenue forecast at $3,082,480,905.
In 2028, FHTX is forecast to generate $1,843,793,293 in revenue, with the lowest revenue forecast at $0 and the highest revenue forecast at $3,172,724,203.